HK1054502A1 - Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide - Google Patents

Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide

Info

Publication number
HK1054502A1
HK1054502A1 HK03106199A HK03106199A HK1054502A1 HK 1054502 A1 HK1054502 A1 HK 1054502A1 HK 03106199 A HK03106199 A HK 03106199A HK 03106199 A HK03106199 A HK 03106199A HK 1054502 A1 HK1054502 A1 HK 1054502A1
Authority
HK
Hong Kong
Prior art keywords
thalidomide
cancer
treatment
compositions
administration
Prior art date
Application number
HK03106199A
Other languages
English (en)
Inventor
Jerome B Zeldis
Andrew Zeitlin
Sol Barer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HK1054502A1 publication Critical patent/HK1054502A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03106199A 2000-05-15 2003-08-29 Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide HK1054502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20414300P 2000-05-15 2000-05-15
PCT/US2001/015327 WO2001087307A2 (fr) 2000-05-15 2001-05-10 Compositions et methodes de traitement du cancer

Publications (1)

Publication Number Publication Date
HK1054502A1 true HK1054502A1 (en) 2003-12-05

Family

ID=22756804

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106199A HK1054502A1 (en) 2000-05-15 2003-08-29 Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide

Country Status (19)

Country Link
US (2) US7435726B2 (fr)
EP (1) EP1307197B1 (fr)
JP (1) JP5409981B2 (fr)
KR (1) KR100790589B1 (fr)
AR (1) AR029084A1 (fr)
AT (1) ATE322266T1 (fr)
AU (2) AU6147401A (fr)
BR (1) BR0110877A (fr)
CA (1) CA2408707C (fr)
DE (1) DE60118571T2 (fr)
DK (1) DK1307197T3 (fr)
ES (1) ES2258084T3 (fr)
HK (1) HK1054502A1 (fr)
MX (1) MXPA02011218A (fr)
NZ (1) NZ522767A (fr)
PT (1) PT1307197E (fr)
TW (1) TWI289449B (fr)
WO (1) WO2001087307A2 (fr)
ZA (1) ZA200209638B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
DE60130799T2 (de) * 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression
DE60209471D1 (de) * 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
CA2383259A1 (fr) * 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
CN1620305A (zh) * 2001-12-14 2005-05-25 株式会社盛多利 诱导凋亡的方法和诱导凋亡的组合物
KR20040097237A (ko) * 2002-03-26 2004-11-17 반유 세이야꾸 가부시끼가이샤 항종양성 인돌로피롤로카바졸 유도체와 기타 항암제의 병용
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1705439A (zh) * 2002-04-12 2005-12-07 细胞基因公司 干细胞和祖细胞分化的调节、鉴定及其应用
WO2003090681A2 (fr) * 2002-04-24 2003-11-06 Research Development Foundation Effets synergetiques des inhibiteurs du facteur nf-kb de transcription nucleaire et d'agents anti-cancereux
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
EP1505973B1 (fr) * 2002-05-17 2010-03-03 Celgene Corporation Combinaisons pour le traitement du myélome multiple
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
KR20050056247A (ko) * 2002-10-15 2005-06-14 셀진 코포레이션 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20090048520A (ko) 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
CA2505003A1 (fr) * 2002-11-06 2004-05-27 Celgene Corporation Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives
EP1611137A1 (fr) * 2003-03-31 2006-01-04 Pfizer Inc. Sels d'inhibiteurs tricycliques de poly(adp-ribose) polymerases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
US20070270504A1 (en) * 2003-06-20 2007-11-22 Avalon Pharmaceuticals, Inc. Identification of Therapeutic Agents Using Genetic Fingerprinting
US7264819B2 (en) * 2003-06-23 2007-09-04 Anticancer, Inc. Lyase treatment for P. carinii
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2005020908A2 (fr) * 2003-08-26 2005-03-10 Research Development Foundation Inhibiteurs selectifs d'activation de stat-3 et utilisations associees
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1694328A4 (fr) * 2003-12-02 2010-02-17 Celgene Corp Procedes et compositions de traitement et de gestion de l'hemoglobinopathie et de l'anemie
WO2005061474A1 (fr) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Procede de preparation d'ingredients pharmaceutiques actifs hydrates et anhydres (api), compositions pharmaceutiques stables preparees a partir de ces derniers et utilisations desdites compositions
EP2033640A2 (fr) * 2004-02-20 2009-03-11 Arqule, Inc. Béta-lapachone pour le traitement du cancer des poumons
WO2005082359A2 (fr) * 2004-02-20 2005-09-09 Arqule, Inc. Procede de traitement du cancer du pancreas
CA2555941A1 (fr) * 2004-02-20 2005-09-09 Arqule, Inc. Procede de traitement du cancer du colon
ES2368741T3 (es) 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
ES2629682T3 (es) 2004-03-29 2017-08-14 University Of South Florida Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
AU2005244768B2 (en) * 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
BRPI0418801A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
MXPA06012701A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
JP5220594B2 (ja) 2005-06-14 2013-06-26 プロトクス セラピューティックス インコーポレイティッド ポア形成修飾タンパク質を用いて良性前立腺肥大症を治療または予防する方法
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
JPWO2007089043A1 (ja) * 2006-02-03 2009-06-25 武田薬品工業株式会社 リポソーム製剤
WO2007127488A1 (fr) * 2006-04-27 2007-11-08 Shenoy Narmada R Compositions et méthodes pour traiter ou prévenir des maladies de voies du corps
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2014651A1 (fr) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Composants et procédés de modulation de Rho GTPases
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2009058394A1 (fr) * 2007-11-01 2009-05-07 Celgene Corporation Analogues de la cytidine destinés au traitement de syndromes myélodysplasiques
US20090264382A1 (en) * 2007-11-21 2009-10-22 David Chaplin Methods for Treating Hematopoietic Neoplasms
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
CA2751892A1 (fr) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo[c]phenanthridines comme agents antimicrobiens
US20120059026A1 (en) 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
WO2011156626A1 (fr) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Agents antimicrobiens
WO2011163610A2 (fr) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Agents antimicrobiens
WO2012092485A1 (fr) 2010-12-31 2012-07-05 Anthrogenesis Corporation Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
WO2013106756A2 (fr) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Agents antimicrobiens
WO2013142712A1 (fr) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Agents anti-microbiens
WO2014180882A2 (fr) * 2013-05-07 2014-11-13 Universitat De Barcelona Traitement des métastases cérébrales d'un cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
EP3313818B1 (fr) 2015-06-26 2023-11-08 Celgene Corporation Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
CA3015768A1 (fr) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Procedes et intermediaires de synthese
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
KR101851470B1 (ko) 2016-12-19 2018-06-11 한림대학교 산학협력단 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물
WO2018183917A1 (fr) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Procédés de synthèse et intermédiaires de synthèse
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
WO1992014455A1 (fr) 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
GB9523493D0 (en) * 1995-11-16 1996-01-17 British Biotech Pharm Preparation of allyl succinate derivatives and starting materials therefore

Also Published As

Publication number Publication date
EP1307197A2 (fr) 2003-05-07
JP5409981B2 (ja) 2014-02-05
US7435726B2 (en) 2008-10-14
ES2258084T3 (es) 2006-08-16
CA2408707C (fr) 2010-04-13
MXPA02011218A (es) 2004-08-19
WO2001087307A2 (fr) 2001-11-22
DE60118571T2 (de) 2007-02-01
ZA200209638B (en) 2003-11-27
AU2001261474B2 (en) 2006-03-09
BR0110877A (pt) 2003-03-11
TWI289449B (en) 2007-11-11
ATE322266T1 (de) 2006-04-15
AR029084A1 (es) 2003-06-04
KR100790589B1 (ko) 2008-01-02
NZ522767A (en) 2004-07-30
PT1307197E (pt) 2006-08-31
EP1307197B1 (fr) 2006-04-05
US20050148524A1 (en) 2005-07-07
WO2001087307A3 (fr) 2002-07-25
AU6147401A (en) 2001-11-26
KR20030025922A (ko) 2003-03-29
US20020035090A1 (en) 2002-03-21
DE60118571D1 (de) 2006-05-18
JP2003533484A (ja) 2003-11-11
CA2408707A1 (fr) 2001-11-22
DK1307197T3 (da) 2006-07-03

Similar Documents

Publication Publication Date Title
HK1054502A1 (en) Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
CR20220614A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
AU6147301A (en) Compositions and methods for the treatment of colorectal cancer
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2002043720A3 (fr) Compositions et methodes de traitement du cancer
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CR20240233A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
AP1780A (en) Use of cox-2 inhibitors for preventing immunodeficiency.
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
EP1503748A4 (fr) Medicaments servant a attenuer la neurotoxicite induite par le taxane
WO2005025501A3 (fr) Co-administration de polysaccharide avec un agent chimiotherapeutique pour le traitement du cancer
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
MX2023001823A (es) Terapia de combinacion.
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
WO2002080895A3 (fr) Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
WO2005039497A3 (fr) Procedes et compositions a base de thalidomide pour le traitement des fibromyalgies
WO2007136615A3 (fr) Thérapie anticancéreuse combinée

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150510